418 related articles for article (PubMed ID: 32132216)
1. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma.
Wang D; Starr R; Chang WC; Aguilar B; Alizadeh D; Wright SL; Yang X; Brito A; Sarkissian A; Ostberg JR; Li L; Shi Y; Gutova M; Aboody K; Badie B; Forman SJ; Barish ME; Brown CE
Sci Transl Med; 2020 Mar; 12(533):. PubMed ID: 32132216
[TBL] [Abstract][Full Text] [Related]
2. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
3. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.
Li X; Zhao L; Li W; Gao P; Zhang N
Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
5. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
6. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
An Z; Hu Y; Bai Y; Zhang C; Xu C; Kang X; Yang S; Li W; Zhong X
Oncoimmunology; 2021; 10(1):1960728. PubMed ID: 34408922
[TBL] [Abstract][Full Text] [Related]
8. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model.
Murty S; Haile ST; Beinat C; Aalipour A; Alam IS; Murty T; Shaffer TM; Patel CB; Graves EE; Mackall CL; Gambhir SS
Oncoimmunology; 2020 May; 9(1):1757360. PubMed ID: 32923113
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin-1 drives tumor-specific uptake of chlorotoxin.
McGonigle S; Majumder U; Kolber-Simonds D; Wu J; Hart A; Noland T; TenDyke K; Custar D; Li D; Du H; Postema MHD; Lai WG; Twine NC; Woodall-Jappe M; Nomoto K
Cell Commun Signal; 2019 Jun; 17(1):67. PubMed ID: 31208428
[TBL] [Abstract][Full Text] [Related]
10. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
11. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Hegde M; Corder A; Chow KK; Mukherjee M; Ashoori A; Kew Y; Zhang YJ; Baskin DS; Merchant FA; Brawley VS; Byrd TT; Krebs S; Wu MF; Liu H; Heslop HE; Gottschalk S; Yvon E; Ahmed N
Mol Ther; 2013 Nov; 21(11):2087-101. PubMed ID: 23939024
[TBL] [Abstract][Full Text] [Related]
12. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.
Hänsch L; Peipp M; Mastall M; Villars D; Myburgh R; Silginer M; Weiss T; Gramatzki D; Vasella F; Manz MG; Weller M; Roth P
Neuro Oncol; 2023 Nov; 25(11):2001-2014. PubMed ID: 37335916
[TBL] [Abstract][Full Text] [Related]
14. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
15. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.
Choe JH; Watchmaker PB; Simic MS; Gilbert RD; Li AW; Krasnow NA; Downey KM; Yu W; Carrera DA; Celli A; Cho J; Briones JD; Duecker JM; Goretsky YE; Dannenfelser R; Cardarelli L; Troyanskaya O; Sidhu SS; Roybal KT; Okada H; Lim WA
Sci Transl Med; 2021 Apr; 13(591):. PubMed ID: 33910979
[TBL] [Abstract][Full Text] [Related]
16. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Bielamowicz K; Fousek K; Byrd TT; Samaha H; Mukherjee M; Aware N; Wu MF; Orange JS; Sumazin P; Man TK; Joseph SK; Hegde M; Ahmed N
Neuro Oncol; 2018 Mar; 20(4):506-518. PubMed ID: 29016929
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Kong S; Sengupta S; Tyler B; Bais AJ; Ma Q; Doucette S; Zhou J; Sahin A; Carter BS; Brem H; Junghans RP; Sampath P
Clin Cancer Res; 2012 Nov; 18(21):5949-60. PubMed ID: 22966020
[TBL] [Abstract][Full Text] [Related]
18. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells.
Sengupta S; Katz SC; Sengupta S; Sampath P
Cancer Lett; 2018 Oct; 433():131-139. PubMed ID: 29959057
[TBL] [Abstract][Full Text] [Related]
20. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]